Clinical trials
Alzheimer clinical trials
Below are recruiting alzheimer clinical trials, each written for real people, not researchers. We’re tracking 622 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07553338RecruitingPhase 2
Leronlimab Safety and Brain Inflammation in Alzheimer's
This study tests whether a drug called leronlimab is safe and can reduce inflammation in the brains of people with mild-to-moderate Alzheimer's disease or memory problems. Researchers will use special brain scans to see if the drug affects inflammation.
New York, New YorkAges 50 years+ - NCT07667478Recruiting
Brain stimulation study for early Alzheimer's memory loss
This study tests whether a non-invasive magnetic brain stimulation technique can help improve memory in people with early Alzheimer's disease. It may be an option if you have mild cognitive impairment or mild dementia due to Alzheimer's and have had a positive blood test for Alzheimer's markers.
Houston, TexasAges 55–90 - NCT05973448Enrolling by invitation
Nightlight Falls Prevention for People With Dementia
This study tests a simple plan to help prevent falls in people who have dementia. You may be able to join if you live in a participating assisted living community and meet the safety and room rules.
Chapel Hill, North CarolinaAges 18 years+ - NCT05882344Enrolling by invitation
Deep brain stimulation for early Alzheimer’s memory problems
This trial tests whether a targeted deep brain stimulation treatment can help people with early Alzheimer’s disease symptoms and memory loss. It also involves brain imaging and a surgery/anesthesia procedure to place the stimulator.
Nashville, TennesseeAges 60–80 - NCT07169630RecruitingPhase 1
PET scan study for Alzheimer's or mild cognitive impairment
This study uses a special PET scan to look at a brain protein called PDE4 in people with Alzheimer's disease or mild cognitive impairment. It may help researchers understand how this protein is involved in memory and thinking problems.
Bethesda, MarylandAges 50–100 - NCT07636811RecruitingPhase 2
Mivelsiran for Early Alzheimer's in Down Syndrome
This trial tests a new drug called mivelsiran designed to slow early-stage Alzheimer's disease in adults with Down syndrome. The drug works by targeting amyloid, a protein that builds up in the brain and causes cognitive decline.
Maitland, FloridaAges 40–55 - NCT07758660Enrolling by invitationPhase 2
Brain scan study for Alzheimer's research
This study uses brain scans (PET) to look at changes in the brain that may be related to memory problems or Alzheimer's disease. It aims to improve understanding of the disease and may help develop better treatments.
New York, New YorkAges 50 years+ - NCT07011732RecruitingPhase 3
Testing a drug for Alzheimer's-related agitation
This study tests an experimental drug (KarXT) to see if it safely reduces agitation in people with Alzheimer's disease. It may help if you or your loved one experiences restlessness, aggression, or irritability related to Alzheimer's.
Scottsdale, ArizonaAges 55–90 - NCT05477862Enrolling by invitation
Improvised music for Alzheimer's anxiety
This study looks at how creating music in the moment (improvisation) affects anxiety and brain function in people with mild to moderate Alzheimer's disease. It may help reduce agitation and improve quality of life.
Chicago, IllinoisAges 55–100 - NCT05926011Recruiting
Test RGn600 in mild to moderate Alzheimer’s patients
This trial studies whether RGn600 can help people with mild to moderate Alzheimer’s disease. You may be able to join if you meet age, test-score, scan, bloodwork, and safety requirements and can attend study visits with a regular caregiver.
CastresAges 55–85 - NCT07239310Recruiting
Device to improve memory and thinking in early Alzheimer's
This study tests a device called Neuclare that aims to temporarily boost memory and thinking skills in people with mild cognitive impairment or very early Alzheimer's disease. It could offer a non-drug way to help with daily mental tasks.
Cheonan, Chungcheongnam-doAges 55–90 - NCT07659964Recruiting
Rhythmic music and walking study for Alzheimer's
This study tests whether listening to a steady beat (rhythmic music) while walking can improve movement and brain function in people with mild Alzheimer's disease. Healthy volunteers are also needed for comparison.
Boston, MassachusettsAges 50–90 - NCT07598370RecruitingPhase 1
Testing LY3439539 for early-stage Alzheimer's disease
This study tests an experimental drug called LY3439539 in people with early-stage Alzheimer's disease. The drug is designed to target protein changes in the brain that may slow memory loss and cognitive decline.
Irvine, CaliforniaAges 50–85 - NCT07459660Enrolling by invitationPhase 2
Long-term study of ML-007C-MA for Alzheimer's psychosis
This trial tests a long-term treatment (ML-007C-MA) for people with Alzheimer's disease who have psychosis. It is for those who already completed an earlier study with the same drug and may benefit from continuing it. The goal is to see if ongoing treatment is helpful and safe.
Anaheim, CaliforniaAges 55–91 - NCT06924359Recruiting
Eye scans and blood tests for early Alzheimer's detection
This study uses special eye scans and blood tests to find early signs of Alzheimer's disease. It aims to detect the disease before memory loss becomes severe, so treatment can start sooner.
BeijingAges 50 years+ - NCT06871839Recruiting
A study of lencanumab for early Alzheimer's disease
This trial tests an investigational drug called lencanumab for people with early Alzheimer's disease. The goal is to see if it can help with memory and thinking by targeting brain changes caused by Alzheimer's.
BeijingAges 50–90 - NCT06731842Enrolling by invitation
Brain scans and blood tests for Alzheimer's disease
This study uses a special brain scan (PET imaging) and blood tests to look for early signs of Alzheimer's and other brain diseases. It aims to improve how we detect and understand these conditions.
StockholmAges 30–85 - NCT04956549Recruiting
Exercise program for early memory loss in African Americans
This study tests whether a structured exercise program can lower Alzheimer’s risk in older African American adults who have mild cognitive impairment (MCI). You’ll be placed by chance into an exercise group or a comparison group and attend group sessions for about a year.
Baton Rouge, LouisianaAges 60 years+ - NCT06189963RecruitingPhase 1/Phase 2
Cell therapy trial for moderate Alzheimer's disease
This trial tests a new immune cell therapy (SNK01) for people with moderate Alzheimer's disease. The goal is to see if it can slow down memory and thinking decline.
Glendale, CaliforniaAges 40–85 - NCT05980949RecruitingPhase 3
Long-term safety study of KarXT for Alzheimer's psychosis
This trial tests the long-term safety of an investigational drug called KarXT for people with psychosis caused by Alzheimer's disease. It is for those who have already completed a previous KarXT study and want to continue treatment.
Homewood, AlabamaAges 55–90 - NCT06126224RecruitingPhase 3
Testing KarXT for Alzheimer's-related psychosis
This clinical trial tests an investigational oral medication called KarXT for treating psychosis (hallucinations or delusions) in people with Alzheimer's disease. The study aims to see if the drug can safely reduce these symptoms.
Chandler, ArizonaAges 55–90 - NCT07262645RecruitingPhase 3
Light therapy for mild to moderate Alzheimer's disease
This study tests a near-infrared light therapy device for people with mild to moderate Alzheimer's disease. It may help with memory and thinking by using light on the head, a non-invasive approach.
Beijing, Beijing MunicipalityAges 50–85 - NCT06889896Enrolling by invitation
Blood test for Alzheimer's brain changes
This study uses a simple blood test to quickly detect Alzheimer's-related brain changes (amyloid plaques). It may help people with memory concerns avoid a more invasive PET scan and get answers faster.
Hefei, AnhuiAges 45–85 - NCT07409506Recruiting
How caregivers help people with Alzheimer's
This study looks at the support that caregivers provide to people with Alzheimer's disease at different stages. It helps researchers understand how caregiving changes over time, which can lead to better support for both patients and their families.
VilleurbanneAges 60 years+
Hear when a new Alzheimer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for alzheimer?
- Yes. Clin2 currently lists 622 recruiting alzheimer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a alzheimer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a alzheimer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.